All In Biotech

Drug Trial Radar · NCT00696631

European Trial of Dronedarone in Moderate to Severe Congestive Heart Failure

Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease

Last checked: Nov 19, 2026Latest source record: Feb 15, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 653 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

653

Actual

Start

Jun 2002

Primary completion

Jan 2003

Study completion Aug 2003

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy, tolerability and safety of dronedarone versus placebo in patients with symptomatic congestive heart failure (CHF) and left ventricular dysfunction (LVD) when added to evidence based treatments for CHF.

Conditions

  • Congestive Heart Failure

Interventions

  • Dronedarone (SR33589)Drug

    oral administration

  • PlaceboDrug

    oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Death from any cause or adjudicated hospitalization for worsening heart failureTime frame: Until study cut-off date

Locations

6 sites in 6 countries. Site status is shown where the registry gives one.

  • Sanofi-aventis Administrative Office

    Hørsholm, Denmark

  • Sanofi-aventis Administrative Office

    Budapest, Hungary

  • Sanofi-aventis Administrative Office

    Gouda, Netherlands

  • Sanofi-aventis Administrative Office

    Lysaker, Norway

  • Sanofi-aventis Administrative Office

    Warsaw, Poland

  • Sanofi-aventis Administrative Office

    Bromma, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.